Carelizumab and rivoceranib for advanced extramammary Paget’s disease: an investigator-initiated multicenter, single-arm, phase II trial
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf202 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, 2025. Verfasst von Sheng Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Shanghai Cancer Center and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200030, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Paget Disease, Extramammary, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Extramammary Paget’s disease (EMPD) is a rare cancer without standard therapy. We evaluated the safety and efficacy of a combination of the humanized monoclonal antiprogrammed death-1 (PD-1) antibody, carelizumab, with rivoceranib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, in patients with advanced EMPD.
Methods
This multicenter, single-arm, phase II trial included 12 patients with EMPD. The primary endpoint is the objective response rate (ORR), defined as the proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST v1.1 criteria. It is hypothesized that the ORR will be less than 10% if the treatment is ineffective and will reach 35% if effective. Secondary endpoints include progression-free survival (PFS) and safety assessments. Eligible patients are aged ≥18 years, with histologically confirmed advanced EMPD. Treatment consists of carelizumab (200 mg intravenously every 3 weeks) and rivoceranib (250 mg orally once daily), with dose adjustments permitted based on toxicity profiles.
Results
Between June 2024 and February 2025, 12 patients were enrolled. One patient withdrew from the trial because of nontreatment-related accidents, and a total of 11 patients completed at least 1 cycle of treatment. The median PFS is 2.4 months (95% CI, 2.1-4.4 months). Among these 11 patients, no patients achieved CR or PR. Six patients (50%) experienced grade 3 adverse events.
Conclusions
This is the first trial evaluating the combination of a PD-1 inhibitor and a VEGFR inhibitor in advanced EMPD. This combination therapy is well tolerated but does not appear to have clinically meaningful activity in advanced EMPD. This trial was registered at the Chinese Clinical Trial number registration: 2400086153.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology, Shanghai Cancer Center and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200030, China.
- Shanghai University of Engineering Science, Shanghai 201620, China.
- Rare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
- Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Affiliated Hospital of Qingdao University, Qingdao 266003, China.
ORCID-Profile: Sheng Zhang
Zitieren
APA
Zhang, S., Ju, M., Wang, Q., Zhu, D., Liu, Z., Ye, X., & Li, W. (2025). Carelizumab and rivoceranib for advanced extramammary Paget’s disease: an investigator-initiated multicenter, single-arm, phase II trial. The Oncologist. https://doi.org/10.1093/oncolo/oyaf202
Vancouver
Zhang S, Ju M, Wang Q, Zhu D, Liu Z, Ye X, et al. Carelizumab and rivoceranib for advanced extramammary Paget’s disease: an investigator-initiated multicenter, single-arm, phase II trial. The Oncologist. 2025. doi:10.1093/oncolo/oyaf202
BibTeX
@article{Zhang2025,
author = {Zhang, Sheng and Ju, Mengyang and Wang, Qin and Zhu, Dongyuan and Liu, Zengjun and Ye, Xiongjun and Li, Wenfeng},
title = {Carelizumab and rivoceranib for advanced extramammary Paget’s disease: an investigator-initiated multicenter, single-arm, phase II trial},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf202}
}
EUVIMED